Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study

Background: Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. Propranolol 0.1% eye micro-drops administered to newborns with stage 2 ROP are well-tolerated, but not sufficiently effective. Methods: A multi-center open-label trial was conducted to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippi, Luca, Cavallaro, Giacomo, Berti, Elettra, Padrini, Letizia, Araimo, Gabriella, Regiroli, Giulia, Raffaeli, Genny, Bozzetti, Valentina, Tagliabue, Paolo, Tomasini, Barbara, Mori, Annalisa, Buonocore, Giuseppe, Agosti, Massimo, Bossi, Angela, Chirico, Gaetano, Aversa, Salvatore, Fortunato, Pina, Osnaghi, Silvia, Cavallotti, Barbara, Suzani, Martina, Vanni, Maurizio, Borsari, Giulia, Donati, Simone, Nascimbeni, Giuseppe, Nardo, Daniel, Piermarocchi, Stefano, la Marca, Giancarlo, Forni, Giulia, Milani, Silvano, Cortinovis, Ivan, Calvani, Maura, Bagnoli, Paola, Dal Monte, Massimo, Calvani, Anna Maria, Pugi, Alessandra, Villamor, Eduardo, Donzelli, Gianpaolo, Mosca, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514240/
https://www.ncbi.nlm.nih.gov/pubmed/31134171
http://dx.doi.org/10.3389/fped.2019.00180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514240/
https://www.ncbi.nlm.nih.gov/pubmed/31134171
http://dx.doi.org/10.3389/fped.2019.00180

Ejemplares similares